ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,496,678 | -31.6% | 182,235 | -11.5% | 0.03% | -27.7% |
| Q2 2023 | $9,504,210 | +14.0% | 206,031 | -0.9% | 0.05% | +4.4% |
| Q1 2023 | $8,335,106 | -21.8% | 207,858 | -9.7% | 0.04% | -26.2% |
| Q4 2022 | $10,664,888 | +36.7% | 230,194 | +22.2% | 0.06% | +19.6% |
| Q3 2022 | $7,803,000 | +301.4% | 188,421 | +478.3% | 0.05% | +325.0% |
| Q2 2022 | $1,944,000 | +764.0% | 32,581 | +1282.3% | 0.01% | +1100.0% |
| Q2 2021 | $225,000 | -87.2% | 2,357 | -84.8% | 0.00% | -90.0% |
| Q1 2021 | $1,761,000 | +383.8% | 15,466 | +489.0% | 0.01% | +400.0% |
| Q4 2020 | $364,000 | -6.4% | 2,626 | -30.9% | 0.00% | -50.0% |
| Q2 2015 | $389,000 | +18.2% | 3,800 | -28.3% | 0.00% | +33.3% |
| Q1 2015 | $329,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |